The Trump administration has made initial comments regarding its approach to drug price negotiations under the Inflation Reduction Act (IRA), focusing on enhancing transparency in the process. Recently, Medicare selected 15 prescription drugs, including popular diabetes and weight-loss treatments like Ozempic and Wegovy, for price negotiations. The government aims to implement improvements to the program while continuing to engage with stakeholders. Meanwhile, pharmaceutical companies such as Novo Nordisk are actively seeking legal pathways to expedite their challenges against the IRA, and organizations like AAM have expressed dissatisfaction with the latest negotiation list. Amid these developments, the US pharmaceutical market remains cautiously optimistic despite pressures from the IRA.